PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease

BACKGROUND: Despite the availability of effective drug therapies that reduce low‐density lipoprotein (LDL)‐cholesterol (LDL‐C), cardiovascular disease (CVD) remains an important cause of mortality and morbidity. Therefore, additional LDL‐C reduction may be warranted, especially for people who are un...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cochrane Database Syst Rev
Egile Nagusiak: Schmidt, Amand F, Carter, John-Paul L, Pearce, Lucy S, Wilkins, John T, Overington, John P, Hingorani, Aroon D, Casas, JP
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley & Sons, Ltd 2020
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8094613/
https://ncbi.nlm.nih.gov/pubmed/33078867
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD011748.pub3
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak